Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 69.11% ano a ano.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 1.20M.
Avaliação Justa
O PE mais recente da empresa é -0.61, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 2.25M ações, um aumento de 33.51% em relação ao trimestre anterior.